The DLB patients with concomitant AD pathology (DLB/AD+) represent a specific diagnostic challenge since abnormal AD biomarkers (such as Aβ-42, tau and p-tau in cerebrospinal fluid (CSF), and amyloid-PET (Scheltens et al., 2016)) can lead to an incorrect diagnosis of AD (Jellinger, 2004). Here, MAPT is linked to Lewy body dementia.